An observational study in Acute Anterior Choroidal Infarction (ACI) and Paramedian Pontine Infarction (IPP), sponsored by Centre Hospitalier Sud Francilien. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.
Sponsored by Centre Hospitalier Sud Francilien · Observational
TITACIPPI (Tirofiban with Intravenous Thrombolysis in Acute Anterior Choroidal Infarction [ACI] and Paramedian Pontine Infarction [IPP]) study aimed to evaluate the efficacy and safety of simultaneous infusion of tirofiban with intravenous thrombolysis (IVT + tirofiban group) compared to IVT alone (IVT alone group) in patients with ACI or PPI. TITACIPPI study is a retrospective, single-center observational study conducted from March 01, 2014, to December 31, 2022.
ACI and PPI are frequently associated with clinical fluctuations, characterized by recurrent transient more or less regressive stereotyped episodes of focal motor deficits affecting the face, arm, and leg, and finally with a risk of lasting neurological worsening that can lead to definite residual neurological disability. These ischemic strokes (ACI and PPI) are not very sensitive to IVT, thus 26% to 48% will experience neurological aggravation despite the administration of this treatment. Studies in Asia have shown a possible clinical benefit of simultaneous infusion of tirofiban with IVT in patients with ischemic stroke of atheromatous or microatheromatous origin without additional bleeding risk. To date, no studies have tested the efficacy of simultaneous infusion of tirofiban and IVT in the well-defined subgroup of ACI and PPI and a non-Asian population.
71 studies on the registry are indexed under Infarction; 15 are open to participants now.
This study's enrollment of 48 is below the median of 119 across 23 observational studies indexed under Infarction.
Browse Infarction studies →Centre Hospitalier Sud Francilien is the lead sponsor of 58 studies on the registry; 13 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study included all patients aged ≥ 18 years with ACI or PPI, negative on FLAIR of the MRI of pretreatment, who had received IVT alone or simultaneous infusion of tirofiban with IVT in the stroke unit of CHSF between March 1, 2014, and December 31, 2022.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
group of patients treated with IVT alone
Procedure: IVT with tenecteplase or alteplase
groups of patients treated with simultaneous infusion of tirofiban and IVT
Procedure: Intervention Name : Tirofiban and IVT with tenecteplase or alteplase
Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
Volume of the ischemic lesion
Evolution of the volume of the ischemic lesion in diffusion-weighted imaging between initial MRI and post-therapy MRI
Time frame: at 24 hours
NIHSS
NIHSS (from 0=favorable to 42=unfavorable)
Time frame: at day 7
Modified Rankin Scale (mRS)
Proportion of the patients with mRS 0-2
Time frame: at 3 months
Secondary neurological deterioration
Rate of secondary neurological deterioration (fluctuations or neurological progression defined as an increase of at least 1 point in NIHSS).
Time frame: at 72 hours
Cerebral hemorrhages
Rates of cerebral hemorrhages defined according to the Heidelberg Bleeding Classification
Time frame: at 24 hours
Systemic bleedings
Rate of significant systemic bleeding (i.e., requiring specific treatment).
Time frame: at 24 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in Sep 2023, 5 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Sud Francilien